Bio Blast Pharma (ORPN) Given Coverage Optimism Rating of 0.16
Press coverage about Bio Blast Pharma (NASDAQ:ORPN) has trended somewhat positive on Wednesday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio Blast Pharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.6874453729602 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, ValuEngine raised Bio Blast Pharma from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th.
Shares of Bio Blast Pharma (ORPN) opened at $1.97 on Wednesday. Bio Blast Pharma has a twelve month low of $1.49 and a twelve month high of $8.55.
COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/15/bio-blast-pharma-orpn-given-coverage-optimism-rating-of-0-16.html.
About Bio Blast Pharma
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Receive News & Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.